These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

114 related articles for article (PubMed ID: 11915169)

  • 1. Dosimetry in a myeloablative setting.
    Breitz H
    Cancer Biother Radiopharm; 2002 Feb; 17(1):119-28. PubMed ID: 11915169
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Marrow toxicity and radiation absorbed dose estimates from rhenium-186-labeled monoclonal antibody.
    Breitz HB; Fisher DR; Wessels BW
    J Nucl Med; 1998 Oct; 39(10):1746-51. PubMed ID: 9776281
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Radiation dosimetry for radionuclide therapy in a nonmyeloablative strategy.
    DeNardo GL; Siantar CL; DeNardo SJ
    Cancer Biother Radiopharm; 2002 Feb; 17(1):107-18. PubMed ID: 11915167
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Radiation dosimetry results and safety correlations from 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials.
    Wiseman GA; Kornmehl E; Leigh B; Erwin WD; Podoloff DA; Spies S; Sparks RB; Stabin MG; Witzig T; White CA
    J Nucl Med; 2003 Mar; 44(3):465-74. PubMed ID: 12621016
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Myeloablative radioimmunotherapy with Re-188-anti-CD66-antibody for conditioning of high-risk leukemia patients prior to stem cell transplantation: biodistribution, biokinetics and immediate toxicities.
    Buchmann I; Bunjes D; Kotzerke J; Martin H; Glatting G; Seitz U; Rattat D; Buck A; Döhner H; Reske SN
    Cancer Biother Radiopharm; 2002 Apr; 17(2):151-63. PubMed ID: 12030109
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Prediction of myelotoxicity based on bone marrow radiation-absorbed dose: radioimmunotherapy studies using 90Y- and 177Lu-labeled J591 antibodies specific for prostate-specific membrane antigen.
    Vallabhajosula S; Goldsmith SJ; Hamacher KA; Kostakoglu L; Konishi S; Milowski MI; Nanus DM; Bander NH
    J Nucl Med; 2005 May; 46(5):850-8. PubMed ID: 15872360
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Correlation of red marrow radiation dosimetry with myelotoxicity: empirical factors influencing the radiation-induced myelotoxicity of radiolabeled antibodies, fragments and peptides in pre-clinical and clinical settings.
    Behr TM; Béhé M; Sgouros G
    Cancer Biother Radiopharm; 2002 Aug; 17(4):445-64. PubMed ID: 12396708
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Red marrow radiation dose adjustment using plasma FLT3-L cytokine levels: improved correlations between hematologic toxicity and bone marrow dose for radioimmunotherapy patients.
    Siegel JA; Yeldell D; Goldenberg DM; Stabin MG; Sparks RB; Sharkey RM; Brenner A; Blumenthal RD
    J Nucl Med; 2003 Jan; 44(1):67-76. PubMed ID: 12515878
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I radioimmunotherapy trial evaluating 90yttrium-labeled anti-carcinoembryonic antigen (CEA) chimeric T84.66 in patients with metastatic CEA-producing malignancies.
    Wong JYC ; Chu DZ; Yamauchi DM; Williams LE; Liu A; Wilczynski S; Wu AM; Shively JE; Doroshow JH; Raubitschek AA
    Clin Cancer Res; 2000 Oct; 6(10):3855-63. PubMed ID: 11051230
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Sacral scintigraphy for bone marrow dosimetry in radioimmunotherapy.
    Siegel JA; Lee RE; Pawlyk DA; Horowitz JA; Sharkey RM; Goldenberg DM
    Int J Rad Appl Instrum B; 1989; 16(6):553-9. PubMed ID: 2481657
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Phase I study of 90Y-labeled B72.3 intraperitoneal administration in patients with ovarian cancer: effect of dose and EDTA coadministration on pharmacokinetics and toxicity.
    Rosenblum MG; Verschraegen CF; Murray JL; Kudelka AP; Gano J; Cheung L; Kavanagh JJ
    Clin Cancer Res; 1999 May; 5(5):953-61. PubMed ID: 10353726
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Practical determination of patient-specific marrow dose using radioactivity concentration in blood and body.
    Shen S; DeNardo GL; Sgouros G; O'Donnell RT; DeNardo SJ
    J Nucl Med; 1999 Dec; 40(12):2102-6. PubMed ID: 10616892
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Bone marrow dosimetry using blood-based models for radiolabeled antibody therapy: a multiinstitutional comparison.
    Wessels BW; Bolch WE; Bouchet LG; Breitz HB; Denardo GL; Meredith RF; Stabin MG; Sgouros G;
    J Nucl Med; 2004 Oct; 45(10):1725-33. PubMed ID: 15471841
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Radiation-absorbed dose estimates to normal organs following intraperitoneal 186Re-labeled monoclonal antibody: methods and results.
    Breitz HB; Durham JS; Fisher DR; Weiden PL
    Cancer Res; 1995 Dec; 55(23 Suppl):5817s-5822s. PubMed ID: 7493352
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Dosimetry and toxicity of Quadramet for bone marrow ablation in multiple myeloma and other haematological malignancies.
    Bartlett ML; Webb M; Durrant S; Morton AJ; Allison R; Macfarlane DJ
    Eur J Nucl Med Mol Imaging; 2002 Nov; 29(11):1470-7. PubMed ID: 12397466
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Targeted total marrow irradiation using three-dimensional image-guided tomographic intensity-modulated radiation therapy: an alternative to standard total body irradiation.
    Wong JY; Liu A; Schultheiss T; Popplewell L; Stein A; Rosenthal J; Essensten M; Forman S; Somlo G
    Biol Blood Marrow Transplant; 2006 Mar; 12(3):306-15. PubMed ID: 16503500
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimation of radiation absorbed doses to the red marrow in radioimmunotherapy.
    Macey DJ; DeNardo SJ; DeNardo GL; DeNardo DA; Shen S
    Clin Nucl Med; 1995 Feb; 20(2):117-25. PubMed ID: 7720301
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Hematologic toxicity in radioimmunotherapy: dose-response relationships for I-131 labeled antibody therapy.
    O'Donoghue JA; Baidoo N; Deland D; Welt S; Divgi CR; Sgouros G
    Cancer Biother Radiopharm; 2002 Aug; 17(4):435-43. PubMed ID: 12396707
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Improved prediction of myelotoxicity using a patient-specific imaging dose estimate for non-marrow-targeting (90)Y-antibody therapy.
    Shen S; Meredith RF; Duan J; Macey DJ; Khazaeli MB; Robert F; LoBuglio AF
    J Nucl Med; 2002 Sep; 43(9):1245-53. PubMed ID: 12215566
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evaluation of methods for red marrow dosimetry based on patients undergoing radioimmunotherapy.
    Hindorf C; Lindén O; Tennvall J; Wingårdh K; Strand SE
    Acta Oncol; 2005; 44(6):579-88. PubMed ID: 16165917
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.